Top Bucket AI

About

Dr. Mikhail Kalinichev is Addex's Head of Translational Science and serves in the equivalent role for the Neurosterix Group under the service agreement between Addex and Neurosterix. He rejoined Addex in August 2021, having previously spent four years at the company in roles including Associate Director and Group Leader, Behavioral Neuroscience. Immediately before rejoining he spent six years as Director of in vivo neurology at Ipsen (France), and earlier was a section head at Lundbeck (Denmark) and a principal scientist at GlaxoSmithKline's Psychiatry Center of Excellence (UK). He has received the Vernalis Prize of the British Association for Psychopharmacology and the GlaxoSmithKline Exceptional Science Award, is an inventor on several patents and has co-authored more than 50 papers. He earned his PhD in behavioural neuroscience at Rutgers University and completed post-doctoral training at Emory University School of Medicine.

Roles

Addex Therapeutics Ltd.

Head of Translational Science · Current role

August 2021–present

Addex Therapeutics

Head of Translational Science · Second tenure; prior 4-year tenure incl. Associate Director / Group Leader, Behavioral Neuroscience

2021 - present

Ipsen

Director, in vivo neurology · Six years (France)

—

Lundbeck

Section head · Schizophrenia, cognitive impairment and pain (Denmark)

—

GlaxoSmithKline

Principal scientist, Psychiatry Center of Excellence · UK

—

External Roles

Neurosterix Group

Head of Translational Science (via service agreement)

present

Fixed Compensation

FY 2025

Direct compensation from Addex

CHF 0

BasisMr. Kalinichev serves as Head of Translational Science under the service agreement between Addex and the Neurosterix Group, provided to Addex at zero cost. He was not one of the two Executive Managers paid directly by Addex in FY2025 (compensation report, FY2025 20-F).